Optimizing Treatments for Heart Failure During Hospitalization

Launched by CENTRAL HOSPITAL, NANCY, FRANCE · Jun 15, 2023

Keywords

ClinConnect Summary

This clinical trial is focused on improving treatments for people who are hospitalized due to worsening heart failure, a condition that affects many individuals in France. Heart failure can lead to serious complications and frequent hospital visits. The study aims to explore how new heart failure medications, including a specific type called iSGLT2, are introduced to patients during their hospital stay. The goal is to better understand how these medications can help manage heart failure and potentially reduce the number of future hospital visits and improve overall health.

To be eligible for this trial, participants need to be at least 18 years old and must be hospitalized for at least 24 hours due to decompensated heart failure, which means their heart isn’t pumping as well as it should. Importantly, the trial is not yet recruiting participants, but once it starts, those who take part can expect close monitoring and support as they receive the new treatments. This study could provide valuable insights into how to best manage heart failure during hospital stays, ultimately benefiting patients and their families.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient ≥ 18 years
• • Hospitalized (≥24h) for decompensated heart failure in cardiology.
• Exclusion Criteria:
• • Patient opposition participation in research and use of data.